Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia

Show full item record



Permalink

http://hdl.handle.net/10138/313780

Citation

Schmaelter , A-K , Labopin , M , Socie , G , Itälä-Remes , M , Blaise , D , Yakoub-Agha , I , Forcade , E , Cornelissen , J , Ganser , A , Beelen , D , Labussiere-Wallet , H , Passweg , J , Savani , B N , Schmid , C , Nagler , A & Mohty , M 2020 , ' Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia ' , Blood cancer journal , vol. 10 , no. 3 , 26 . https://doi.org/10.1038/s41408-020-0296-3

Title: Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia
Author: Schmaelter, Ann-Kristin; Labopin, Myriam; Socie, Gerard; Itälä-Remes, Maija; Blaise, Didier; Yakoub-Agha, Ibrahim; Forcade, Edouard; Cornelissen, Jan; Ganser, Arnold; Beelen, Dietrich; Labussiere-Wallet, Helene; Passweg, Jakob; Savani, Bipin N.; Schmid, Christoph; Nagler, Arnon; Mohty, Mohamad
Contributor: University of Helsinki, HUS Comprehensive Cancer Center
Date: 2020-03-03
Language: eng
Number of pages: 9
Belongs to series: Blood cancer journal
ISSN: 2044-5385
URI: http://hdl.handle.net/10138/313780
Abstract: Following chemotherapy, secondary acute myeloid leukemia (sAML), occurring after antecedent hematologic diseases, previous chemotherapy or radiation, has an inferior prognosis compared with de novo AML. To define the outcome of sAML in the context of allogeneic stem cell transplantation (alloSCT), a retrospective, registry-based comparison was performed, including 11,439 patients with de novo and 1325 with sAML. Among transplants in first complete remission (CR1) (n = 8,600), the 3-year cumulative incidence of relapse (RI) and non-relapse mortality (NRM) was 28.5% and 16.4% for de novo, and 35% and 23.4% for sAML. Three-year overall survival (OS), leukemia-free survival (LFS) and Graft-versus-Host Disease/relapse-free survival (GRFS) was 60.8%, 55.1%, and 38.6% for de novo, and 46.7%, 41.6%, and 28.4% for sAML, respectively. In multivariate analysis, sAML was associated with a lower OS (HR = 1.33 [95% CI = 1.21-1.48]; p <10(-5)), LFS (HR = 1.32 [95% CI = 1.19-1.45]; p <10(-5)) and GRFS (HR = 1.2 [95% CI = 1.1-1.31]; p <10(-4)) and higher NRM (HR = 1.37 [95% CI = 1.17-1.59]; p <10(-4)) and RI (HR = 1.27 [95% CI = 1.12-1.44]; p <10(-3)). Results of the Cox model were confirmed in a matched-pair analysis. In contrast, results did not differ between de novo and sAML after alloSCT in induction failure or relapse. Hence, this analysis identified sAML as an independent risk factor for outcome after alloSCT in CR1.
Subject: AML
THERAPY
SURVIVAL
CYTOGENETICS
RELAPSE
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41408_020_0296_3.pdf 689.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record